
A December 28 analyst review upheld a buy rating on XMMO but warned the fund was getting expensive. The valuation risk now defines the ETF's profile.
A December 28, 2025 analyst review of the Invesco S&P MidCap Momentum ETF (XMMO) upheld a "buy" rating. The same note added a warning: the fund was getting expensive. That split between a positive rating and a valuation flag creates a concrete risk event for anyone holding or considering the ETF.
The analyst disclosed a beneficial long position in XMMO through stock ownership, options, or other derivatives. That context matters. The caution came from someone who still wanted to own the fund, not from a seller. It makes the valuation concern more credible, not less.
XMMO selects mid-cap stocks with the strongest trailing price momentum and rebalances quarterly. That mechanical approach paid off as AI-related names in the mid-cap space rallied. The December 28 note did not downgrade the fund. It flagged that the price paid per unit of momentum had risen. In practical terms, the ETF's holdings were no longer cheap relative to their own histories.
Momentum as a factor works until it does not. When a momentum fund gets expensive, the next rebalance can lock in losses if the leaders reverse. The analyst's disclosure of a long position adds weight: the warning came from someone who still wanted to own the fund, not from a seller.
Mid-cap momentum ETFs are exposed to two forces that can move independently. The first is the momentum factor itself. If the stocks that drove recent returns begin to lag, the ETF's next quarterly rebalance will sell them and buy the new leaders. That process creates a lag that can amplify drawdowns.
The second force is broad sentiment toward AI and growth stocks. XMMO's recent success came partly from overweight positions in AI-exposed mid-caps. If that sentiment cools on a macro shock or a rotation into value, the fund's valuation premium becomes a liability.
The current setup also carries an execution risk tied to liquidity. Mid-cap stocks generally trade thinner than large caps. If a rebalance coincides with a rush for the exit, the ETF could experience tracking error or wider bid-ask spreads. The December 28 note did not model that scenario. It is a logical extension of the valuation concern.
The most straightforward de-risking event would be a meaningful pullback in XMMO's top holdings. That would compress the valuation premium without breaking the momentum trend. It would give new buyers a better entry while preserving the fund's mechanical edge.
A second de-risking signal would be a shift in the S&P MidCap 400 index composition that introduces cheaper momentum names into the selection pool. Both are passive outcomes that do not require the analyst to change their rating.
The primary risk amplifier is a sudden reversal in AI sentiment that hits the fund's largest sector weights. If that reversal coincides with the quarterly rebalance window, XMMO could be forced to sell into weakness.
A secondary amplifier is a broader liquidity crunch in mid-cap equities. That would make the fund's momentum strategy more expensive to execute. Neither scenario is the base case. The December 28 valuation warning makes them worth monitoring.
For now, the tension between momentum and valuation defines XMMO's risk profile. The next quarterly rebalance and the next batch of mid-cap earnings will serve as the first test of whether the ETF's AI tailwind can absorb the price it now commands. Investors who bought before the December 28 caution should watch the fund's price-to-momentum ratio as a lead indicator. Those looking to enter should wait for a compression.
For a broader perspective on momentum factor risks, see our stock market analysis. For ETF-specific execution details, the best stock brokers guide covers how providers handle rebalance risk.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.